Related Experiment Video
Updated: Jun 23, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
Published on: June 7, 2016
Deciphering the miRNA-mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An
Ambritha Balasundaram1, Tanisha Saurav Mitra1, Iftikhar Aslam Tayubi2
1Laboratory of Integrative Genomics, Department of Integrative Biology, School of BioSciences and Technology, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.
Abstract:
Breast cancer (BC) is globally recognized as the second most prevalent form of cancer. It predominantly affects women and can be categorized into distinct types based on the overexpression of specific cancer receptors.The key receptors implicated in this context are the human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER), and progesterone receptor (PR), alongside a particularly intricate subclass known as triple-negative breast cancer (TNBC). This subclassification is critical for the stratification of breast cancer and informs therapeutic decision-making processes. Due to a lack of therapeutic targets, such as growth factor receptors, TNBC is the most aggressive type. Hence, identifying targetable regulators such as miRNAs could pave the way for potential therapeutic interventions. To identify common differentially expressed mRNAs (DE-mRNAs) in BC, including TNBC, we leveraged two data sets from the GEO collection and The Cancer Genome Atlas (TCGA). Significant DE-mRNAs were identified through PPI, MCODE, CytoNCA, and CytoHubba analyses. Following this, miRNAs were predicted using mirDIP. We utilized GSE42568, GSE185645, and TCGA and identified 159 common DE-mRNAs. Using Cytoscape plug-ins, we identified the 10 most significant DE-mRNAs in BC. Using mirDIP, target miRNAs for 10 DE-mRNAs were identified. We conducted an advanced analysis on the TNBC GEO data set (GSE45498) to corroborate the significance of shared DE-mRNAs and DE-miRNAs in TNBC. We identified four downregulated DE-miRNAs, including hsa-miR-802, hsa-miR-1258, hsa-miR-548a-3p, and hsa-miR-2053, significantly associated with TNBC. Our study revealed significant miRNA-mRNA interactions, specifically hsa-miR-802/MELK, hsa-miR-1258/NCAPG, miR-548a-3p/CCNA2, and hsa-miR-2053/NUSAP1, in both BC and TNBC. The observed downregulation of hsa-miR-548a-3p is associated with diminished survival rates in BC patients, emphasizing their potential utility as prognostic indicators. Furthermore, the differential expression of mRNAs, including CCNB2, UBE2C, MELK, and KIF2C, correlates with reduced survival outcomes, signifying their critical role as potential targets for therapeutic intervention in both BC and TNBC. These findings highlight specific regulatory mechanisms that are potentially crucial for understanding and treating these cancer types.
Insights
This study identifies key microRNAs (miRNAs) and messenger RNAs (mRNAs) involved in breast cancer (BC) and triple-negative breast cancer (TNBC). Downregulated miRNAs like hsa-miR-548a-3p show potential as prognostic indicators for BC patients.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Breast cancer (BC) is a leading global cancer, with subtypes like triple-negative breast cancer (TNBC) lacking specific therapeutic targets.
- Identifying novel regulatory molecules, such as microRNAs (miRNAs), is crucial for developing targeted therapies for aggressive BC subtypes.
- Current BC classification relies on receptor status (HER2, ER, PR), necessitating further molecular stratification.
Purpose of the Study:
- To identify common differentially expressed messenger RNAs (DE-mRNAs) in breast cancer (BC), including triple-negative breast cancer (TNBC).
- To predict and validate microRNAs (miRNAs) that target these DE-mRNAs, focusing on their role in BC and TNBC.
- To explore the potential of identified miRNAs and mRNAs as therapeutic targets and prognostic biomarkers for BC.
Main Methods:
- Utilized publicly available datasets (GEO, TCGA) to identify 159 common DE-mRNAs across BC and TNBC.
- Employed network analysis tools (Cytoscape plugins) to pinpoint the top 10 significant DE-mRNAs.
- Predicted target miRNAs using mirDIP and validated key miRNA-mRNA interactions in TNBC datasets.
Main Results:
- Identified significant miRNA-mRNA interactions, including hsa-miR-802/MELK, hsa-miR-1258/NCAPG, miR-548a-3p/CCNA2, and hsa-miR-2053/NUSAP1, in both BC and TNBC.
- Discovered four downregulated DE-miRNAs (hsa-miR-802, hsa-miR-1258, hsa-miR-548a-3p, hsa-miR-2053) significantly associated with TNBC.
- Found that downregulation of hsa-miR-548a-3p correlates with reduced BC patient survival, while altered expression of mRNAs like CCNB2, UBE2C, MELK, and KIF2C is linked to poorer outcomes.
Conclusions:
- Specific miRNA-mRNA interactions represent crucial regulatory mechanisms in BC and TNBC.
- Downregulated hsa-miR-548a-3p serves as a potential prognostic indicator for breast cancer.
- Aberrantly expressed mRNAs (CCNB2, UBE2C, MELK, KIF2C) are promising therapeutic targets for both BC and TNBC.
Related Concept Videos
MicroRNAs
lncRNA - Long Non-coding RNAs

